Introduction
Since Withering's use of digoxin more than 200 Shifting paradigms in heart failure years ago, a 'magic bullet' to treat heart failure (CHF)
The accepted pathophysiology and treatment of heart has been desperately sought. Among the reasons for failure has evolved over the past 50 years. The this enthusiasm is CHF's sobering morbidity, accounthaemodynamic model has given way to the neuroing for greater than 5% of hospital admissions in hormonal hypothesis, which implicates the activation the UK, and greater than a million admissions per of sympathetic and renin-angiotensin-aldosterone annum in the US.1,2 Similarly, the associated mortalsystem as the primary determinants of the heart ity of severe heart failure, although not perceived as failure syndrome. 4 This shift was principally driven such, is as severe as that of most cancers, with a by the notable failure of cardiac inotropes to ameliormortality, in those moderately symptomatic at entry, ate heart failure, an important prediction made by of about 80% over 5 years.3 These figures outline proponents of the haemodynamic model, and by the the need for effective therapy. Though the past 20 remarkable efficacy of angiotensin-convertingyears have been exciting times for heart failure enzyme inhibitors (ACE-I), b-blockers and aldactoneresearch, current treatments are still woefully inadantagonists as predicted by the neuro-hormonalists. equate in reducing this high mortality. This means This shift has been consolidated and extended by that novel and effective treatments are still desperthe inclusion of paracrine and cytokine elements ately needed. In this article we explore the role of such as endothelin, bradykinin, nitric oxide, TNF-a TNF-a in the pathogenesis of CHF, and that of and IL-10 into the pathogenesis of heart failure thalidomide, acting as a TNF-a antagonist, as a (Table 1) . potential novel adjunct for the for the management of heart failure.
Among these more novel factors, TNF-a, a trimeric Table 3 Cardiovascular actions of TNF-a Table 1 Inflammatory mediators increased in heart  failure  Triggers release of most inflammatory cytokines and  arachidonic acid metabolites  Tumour necrosis factor-alpha (TNF-a)6  Soluble TNF receptors 1 & 213,54  Can create/organize immune granulomas/lymphocyte  infiltrates  Elevated ratios of TNF-a/soluble TNF receptors54  Interleukin-154-56  Increases iNOS enzyme  Increases amino acid transporters needed for L-arginine  Interleukin-654,55  Enhanced interleukin-6 bioactivity54 (NO precursor) uptake Increases NO production Soluble interleukin-6 receptor, glycoprotein (gp) 13054
(but see reference 57) Induces and enhances the production of reactive oxygen species Interleukin-6/soluble gp130 ratio54 Vascular cell adhesion molecule-1 (VCAM-1)58
Induces free-radical-scavenging enzymes (mitochondrial superoxide dismutase and heat-shock proteins) Intercellular cell adhesion molecule-1 (ICAM-1)55 Endotoxin (oedematous heart failure) 13 Decreases myocardial contractile response to isoprenaline Soluble CD14 (relates to endotoxin-cell interactions)13 C-reactive protein (oedematous heart failure) 13, 59 Decreases resting myocardial contraction (reduced ejection fraction) Uric acid55
Decreases L-type calcium current in myocytes Anti-anbolic and pro-catabolic effects in peripheral 17-kDa protein, a potent cytokine and anti-tumour skeletal muscle proteins Relates to endothelial dysfunction in heart failure factor, seems to be particularly important in CHF (Tables 2 and 3 ). In 1990, while TNF-a was being used as an anti-tumour agent in renal carcinoma, a macrophages. Bacterial lipopolysaccharides and patient thus treated developed severe left ventricular Gram-positive cell wall components after engagefailure consistent with CHF.5 This prompted further ment with their binding protein, interact with toll study of the role of TNF-a in established heart failure.
proteins such as CD14, and are capable of activating These investigations found increased levels of serum signalling pathways that result in the release of TNF-TNF-a in severe CHF.6,7 TNF-a levels correlated with a from macrophages.12 CD14 levels are increased in functional class (exercise capacity) and severity of heart failure, consistent with TNF-a production from the haemodynamic compromise.8,9 Furthermore, the LPS-stimulated macrophages. 13 Where the LPS origin-SOLVD trial (Studies on Left Ventricular Dysfunction) ates is unknown, but according to one hypothesis, found progressive increases in TNF-a levels in those the bowel wall in CHF patients, when congested, is who developed symptomatic heart failure.8 Finally, leaky and allows bacterial lipopolysaccharide transjust as seen in the adrenergic system in heart failure, location from bowel lumen to the blood, thus an adaptive 30-40% downregulation of cardiac TNF allowing LPS-macrophage interaction as the substrate receptors was also found, suggesting ongoing TNF-a for TNF-a in common CHF.13 T cells are also capable receptor and second-messenger activation. [8] [9] [10] of similarly stimulating macrophages, though data as Investigations to identify the source of the TNF-a to whether this occurs in heart failure are not, as synthesis suggested that injured cardiomyocytes from yet, available. Finally excess mechanical stress to failing hearts were a highly relevant and potent the heart, be it pressure or volume overload, results source of this cytokine as in, for example, viral in a cellular stimulus that in turn leads to increased myocarditis, cardiac allograft rejection and myocardlevels of TNF-a mRNA, protein product expression ial infarction.10,11 Other possible sources of TNF-a and TNF-a release.14 These important data suggest in CHF are classical immunological cells such as that any significant insult to the heart, such as a remote myocardial infarct, may initiate TNF-a pro- infusions of TNF-a induced and sustained CHF.15 decrease the contractile responsiveness of the myocyte to b-adrenergic stimulation, thus emphasizThe creation of transgenic mice expressing cardiac TNF-a and developing severe heart disease was ing the complex interactions between known and unknown mediators in heart failure.11,23 TNF-a may further compelling proof for the ability of TNF-a to mediate heart failure.16-18 Interestingly, familial hibalso act to modulate the role of other detrimental cytokines, such as IL-6 and IL-10, in exacerbating ernian fever (FHF), one of the familial fever syndromes, has been found to be due to a missense heart failure. Although none of these have yet been proven to be the major mechanism, it is likely that mutations in the gene encoding type I tumour necrosis factor receptor, and is associated with high a combination of these factors and others will synergize to produce the cumulative damage seen levels of TNF.19 Curiously, the incidence of heart failure appears to be low in FHF, for reasons which in heart failure. Interestingly, there is now accumulating evidence that not only can TNF-a result in the are not clear, but which may either include the need of TNF-a to synergize with other neuro-endocrine, progressive cardiac compromise seen in heart failure, but it can also result in some of the peripheral cytokine and myocardial pathologies to produce the heart failure syndrome, or, more likely, given the circulatory abnormalities that are so central to the heart failure syndrome. Compelling proof for this TNF-RI receptor deficiency, the inability of the high levels of TNF-a to produce a valid intracellular statement comes from the finding of a close relationship between the severity of peripheral endothelial signal. Polymorphisms of TNF and its associated genes occur in human populations, and some, such dysfunction in heart failure and TNF-a levels.23 This may relate to TNF-a inducing oxidative stress in as those affecting the TNF-a promoter gene (the TNF A2 polymorphism) are associated with endothelial cells, thus destroying local NO production and inducing apoptosis.24 Furthermore, TNF-a high TNF levels and an increased susceptibility to inflammatory disease.20,21 Interestingly, in human may also be directly involved in the skeletal muscle cell wasting and fibrosis that is such a prominent CHF this polymorphism is not associated with higher TNF levels and thus, not surprisingly, does component of the advanced heart failure syndrome.14,23 not seem to occur more frequently in heart failure.20,21 However, despite these disappointing findComplicating this apparently straightforward picture of TNF-a as a harmful molecule (the 'conductor' ings in genetic studies in humans, all the other available data suggests that the actions of TNF-a are of a 'harmful orchestra') in heart failure is the finding that TNF-a has highly complex actions, some of a critical component of myocardial depression and remodelling, central to the pathology of CHF.
which are contradictory. For example, TNF-a has been shown in different situations to be catabolic or The mechanism(s) of action(s) that may render TNF-a cardiotoxic have also remained elusive. In anabolic, to induce iNOS (and thus NO), as well as to result in oxidative stress that consumes NO, to be general, TNF-a operates through two transmembrane receptors, TNF-RI (55 kDa) and TNF-RII (75 kDa), involved in cachexia as well as obesity, to be involved in septic shock as well as, through the each extracellular portion having four cysteine domains and considerable homology (implying siminduction of heat-shock proteins and the free radical scavenger mitochondrial superoxide dismutase, proilar extracellular properties) and each intracellular domain having little homology (implying different tection from shock. Which of these different actions predominate probably depends on timing of release, intracellular functions). It appears that TNF-RI is mainly responsible for gene induction and cell death, dose and duration of action in the circulation.14 This (so-called) double-faceted action of TNF-a implies whereas TNF-RII acts to amplify signals. Intracellular signalling is dependent on associated kinases, as that it is extremely difficult to predict the net result of TNF-a activity, and whether it is are really harmful, TNF-RI itself has no kinase activity. Curiously TNF-RI, unlike TNF-RII, can self-associate and produce cell helpful, or indeed neutral.14 Thus, to determine whether elevated levels of TNF-a really are dangerdeath, a process normally inhibited by the very low expressed levels of TNF-RI on the cell membrane. ous in CHF, the result of blocking its action should be determined in the heart failure syndrome. As to the specifics of why TNF-a should be detrimental in cardiovascular disease, there have been suggestions that high levels of TNF-a are toxic in heart failure through direct immunotoxicity, through Current anti-TNF treatments in heart NO-mediated damage, via increased toxic calcium failure oscillations, by apoptosis through TRADD death receptors, by transcriptional activation of elements We suggest therefore that, even in the context of increased TNF-a in CHF patients and its fall in such as NF-KB and also energetic dysfunction leading to sarcomeric function embarrassment. 22 There is response to effective heart failure treatment, formal proof of a role for TNF-a in the heart failure syndrome evidence that one of the effects of TNF-a is to can only be shown by directly reducing this cytokine Alternatively, it has been suggested that as NF-kB is activated by oxidative stress, it might, at least theoretand then either inducing remission or slowing the progression of CHF.13,25,26 Though it is clear that ically, be decreased by vitamin E. However, it seems as though this approach is only theoretically helpful, successful treatment per se of acute exacerbations of the heart failure syndrome reduces inflammatory as the results of the vitamin E post-myocardialinfarction trials, in which significant numbers of mediators, data as to whether chronic conventional treatments influence TNF is very sketchy. The action patients with heart failure were included, have not produced encouraging results.32 It has also been of b-blockers is unknown, but by extension from work in sepsis, is unlikely to be great.27 Some studies suggested that if LPS in heart failure arises from the bowel, that bowel 'purging' to minimize bacteria suggest that ACE-Is reduce TNF levels in vitro but not in vivo.28,29 Worryingly, amiodarone treatment with translocating LPS may be helpful.13 Finally, there are drugs whose actions include depression of appears to increase TNF-a levels in ischaemic heart failure.27 Given these disappointing findings with TNF-a levels, and thus which theoretically may be helpful, but whose other actions are so overwhelminconventional therapies, novel treatments have been looked for. To this end a recombinant soluble p75 gly dangerous as to render the overall action negative. Such drugs include the positive inotropic agent TNF-a receptor protein has been synthesized (which contains two molecules of the extracellular portion vesnarinone, which has been shown to decrease TNF-a levels, by increasing intracellular cAMP levels, of sTNF-R2 linked to the Fc portion of the IgG1 molecule), which has been shown to be safe and is and which is also a potassium channel antagonist. These latter actions may account for the increased capable of reducing the raised levels of TNF-a (through TNF-a sequestration) and concomitantly mortality seen with vesnarinone in heart failure.33,34 These data emphasize that for an anti-TNF-a drug to lessening the severity of heart failure in patients with NYHA Class III CHF.30 Patients in this study be useful in heart failure, it should not only be highly effective in reducing TNF-a levels, but also showed sufficiently increased exercise tolerance, ejection fraction and reported life scores to prompt should have minimal or only positive other actions, should be orally active and cheap. As yet, no drug the initiation of a much larger prospective trial (named RENAISSANCE, for Randomized Etanercept fits this description. North American Strategy to Study AntagoNism of CytokinEs), which aims to reduce TNF-a levels by using the p75 TNF receptor fusion protein
Thalidomide as an anti-TNF-a drug (Etanercept) to verify these results. However, one of and its role in heart failure the problems with using this approach to decrease TNF-a levels is that Etanercept needs to be infused, Thalidomide's use as a drug was initially terminated, after its use in the 1950s and 1960s in pregnant and that as Etanercept is fairly rapidly broken down in vivo (over 7-14 days, though TNF levels remain women was associated with severe birth defects. 35 In addition to causing serious foetal deformities depressed for >14 days), infusions may need to be repeated frequently to achieve long-term TNF-a sup-(phocomelia), thalidomide has been associated with other adverse reactions such as permanent peripheral pression. Furthermore, repeated infusions of TNF receptors may, paradoxically, increase TNF levels.
neuropathy. Despite its poor reputation, thalidomide has recently been found to be extremely effective in An orally active and persistently effective anti-TNF-a agent is needed. Pentoxifylline, an antitreating a variety of conditions such as leprosy, cancers, HIV, cachexia and, most recently, inflammatory agent that inhibits endotoxaemia and lipopolysaccharide (LPS)-induced release of TNF-a myeloma.36-39 It appears that there are numerous mechanisms to has been used in a small study of heart failure due to dilated cardiomyopathy, where it improved both account for this efficacy in diverse disorders. In cancer treatment, for example, thalidomide may act exercise capacity and ejection fraction. 31 The success of this early study has been criticized, in that the as a potent angiogenic inhibitor.40 It does however seem that thalidomide's best-recognized action has decrease in TNF-a levels in placebo and treatment groups was roughly the same.13 Nonetheless, these consistently been its powerful anti-TNF-a activity, although it does have a multiplicity of other actions data are felt sufficiently encouraging to justify further larger-scale studies investigating whether pentoxifyl- (Table 4) . 41, 42 This activity has been ascribed to a powerful specific transcriptional inhibitor effect, line will reduce mortality.
Other approaches to TNF-mediated cardiac disbinding to critical cell proteins and interruption of a phorbol-ester-sensitive pathway by different ease include inhibition of the TNF transcriptional factor NF-kB using pyrrolidine-dithiocarbamates, groups.43,44 Whatever the mechanism, this anti-TNFa effect appears to be robust and reproducible.45 although the specificity of this drug is felt to be low, and its systemic side-effects are unknown.14 Amino-substituted thalidomide analogues may have In those with advanced heart failure, with its attendant high mortality, patients may be particularly useful in heart failure, as they also inhibit LPS-induced monocyte inflammatory may be prepared, with careful monitoring, to take the risk of this complication. cytokines. 47 The role of thalidomide in human heart failure has not been explored, although intriguingly, For these reasons, although the FDA has approved the use of thalidomide in a number of conditions, thalidomide has been found to blunt the development of the (TNF-a-related) circulatory abnormalities in and other late-phase trials are in progress, it may prove important to use analogues of thalidomide that animal models of portal hypertension. 48 We therefore contend that in the CHF population retain TNF-a suppressing qualities but that avoid unacceptable side-effect profiles. It may also be group, a population that is almost completely devoid of pregnant women, thalidomide could, acting necessary to assess pharmacokinetic and in due course pharmacogenomic properties of these drugs through its anti-TNF-a mechanism, ameliorate heart failure.
and patients in the context of differing underlying aetiologies for the syndrome of CHF to optimize its This suggestion of course raises a number of issues. The first is that of long-term efficacy and use. If the thalidomide is capable of acting at the site of TNF-a production, studies with it, in conjuncsafety. The source and mechanism of TNF-a in heart failure has not yet been proven, and if through nontion with the RENAISSANCE trial, may identify anti-TNF-a medications as useful adjuncts in the treatment classical pathways, may not be amenable to thalidomide.47 Furthermore, as CHF is a spectrum of of heart failure. disease with a multitude of underlying causes, thalidomide may be relevant to only some varieties. On the other hand, the cardiomyopathy of heart failure
